Jefferies London 2026: Valneva CEO Thomas Lingelbach shares an update on the status of the company's Lyme disease program (partnered with Pfizer) and more pipeline projects
Updated: 1 day ago
He discusses the regulatory status of Lyme disease, which hit on secondary endpoints in its phase three trial but narrowly missed the primary. Plus, updates on chikungunya and shigella.
Coverage brought to you by










.png)
